Search
AEOL-10150
go.drugbank.com/drugs/DB05874ExperimentalAEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Propacetamol
go.drugbank.com/drugs/DB09288Investigational[A32051] It is a derivative of [acetaminophen], or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. … [A7892] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[L1505]
Golotimod
go.drugbank.com/drugs/DB05475InvestigationalSCV-07 has shown efficacy in treating various viral and bacterial infections. … In independent studies, treatment of tuberculosis with SCV-07 improved clearance of mycobacteria, improved cavity healing, improvements in immune parameters and reduced symptoms (fever, weakness, sweating
GI-5005
go.drugbank.com/drugs/DB05942InvestigationalTarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.
Categories: Complex MixturesAmbenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnIt is used in the management of myasthenia gravis.
Gemigliptin
go.drugbank.com/drugs/DB12412InvestigationalGemigliptin is under investigation in Type 2 Diabetes Mellitus. Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.
Categories: Drugs Used in DiabetesQuinacrine
go.drugbank.com/drugs/DB01103InvestigationalAn acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. … It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
Dexanabinol
go.drugbank.com/drugs/DB06444InvestigationalCategories: Compounds used in a research, industrial, or household settingTRGFT-201
go.drugbank.com/drugs/DB23064ApprovedInvestigational[L64070,L64071] This composition is designed to improve survival free of chronic GVHD compared with a conventional transplant. … [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic
Tesevatinib
go.drugbank.com/drugs/DB11973InvestigationalIn addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. … In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.